{"analyses":[{"ciLowerLimit":"0.53","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.83","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0003","paramType":"Hazard Ratio (HR)","paramValue":"0.66","statisticalComment":"The Log-Rank test was stratified by the Memorial Sloan-Kettering Cancer Center (MSKCC) risk group and number of prior VEGFR TKIs.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Too few events to estimate the upper limit of the confidence interval.","groupId":"OG000","lowerLimit":"18.7","upperLimit":"NA","value":"21.4"},{"groupId":"OG001","lowerLimit":"14.7","upperLimit":"18.8","value":"16.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"330"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"description":"Overall Survival (OS) is defined as the time from randomization to the date of death. Participants that had not died were censored at last known date alive. Median OS was calculated using Kaplan-Meier estimates. Interim analyses for OS occurred after 320 deaths (78% of the total OS events needed for final analysis).","dispersionType":"95% Confidence Interval","groups":[{"description":"Cabozantinib (XL184) 60 mg tablet once daily.\n\nCabozantinib tablets","id":"OG000","title":"Cabozantinib (XL184)"},{"description":"Everolimus (Afinitor) 10 mg tablet once daily.\n\nEverolimus (Afinitor) tablets","id":"OG001","title":"Everolimus (Afinitor)"}],"paramType":"NUMBER","populationDescription":"The Intent to Treat (ITT) population was used and included 658 randomized subjects (330 cabozantinib, 328 everolimus) in the second interim analysis with a cutoff date of 31 December 2015.","reportingStatus":"POSTED","timeFrame":"OS was measured from the time of randomization until 320 deaths, approximately 28 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}